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The acute respiratory distress syndrome (ARDS) was 
initially defined in 1967 with a case- based report that 
described the clinical presentation in critically ill adults 
and children of acute hypoxaemia, noncardiogenic pul-
monary oedema, reduced lung compliance (increased 
lung stiffness), increased work of breathing and the need 
for positive- pressure ventilation in association with sev-
eral clinical disorders including trauma, pneumonia, 
sepsis and aspiration1. In 1992, an American–European 
consensus conference established specific diagnostic 
criteria for the syndrome2; these criteria were updated 
in 2012 in the so- called Berlin definition3 of ARDS in 
adults (Box 1). Depending on the level of oxygenation, 
‘mild’, ‘moderate’ and ‘severe’ descriptors can be added 
to the diagnosis of ARDS (Box 1). The diagnosis of ARDS 
depends on clinical criteria alone because it is not prac-
tical to obtain direct measurements of lung injury by 
pathological samples of lung tissue in most patients; 
furthermore, neither distal airspace nor blood samples 
can be used to diagnose ARDS.
ARDS develops most commonly in the setting of 
pneumonia (bacterial and viral; fungal is less common), 
nonpulmonary sepsis (with sources that include the peri-
toneum, urinary tract, soft tissue and skin), aspiration 
of gastric and/or oral and oesophageal contents (which 
may be complicated by subsequent infection) and major 
trauma (such as blunt or penetrating injuries or burns). 
Several other less common scenarios are also associated 
with the development of ARDS, including acute pan-
creatitis; transfusion of fresh frozen plasma, red blood 
cells and/or platelets (that is, transfusion- associated 
acute lung injury (TRALI)); drug overdose with various 
agents; near drowning (inhalation of fresh or salt water); 
haemorrhagic shock or reperfusion injury (including 
after cardiopulmonary bypass and lung resection); and 
smoke inhalation (often associated with cutaneous 
burn injuries). Other causes of noncardiogenic pulmo-
nary oedema that are often considered as additional 
aetiologies of ARDS include primary graft dysfunction 
following lung transplantation, high- altitude pulmo-
nary oedema, neurogenic oedema (following a central 
nervous system insult or injury) and drug- induced lung 
injury. The frequency of the clinical disorders associ-
ated with ARDS varies depending on the geographical 
location, the health- care systems that are available and 
whether they are resource- rich or resource- poor.
In the past 50 years, considerable progress has been 
made in understanding the epidemiology, pathogenesis 
and pathophysiology of ARDS. In addition, randomized 
trials to optimize mechanical ventilation and fluid 
therapy for ARDS have resulted in improved clinical 
outcomes. Although much progress has been made to 
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improve supportive care for ARDS, effective pharmaco-
logical therapies for ARDS have not yet been identified. 
However, ARDS is increasingly being recognized as a 
heterogenous syndrome, generating momentum to iden-
tify clinical and biological features to classify patients 
into subphenotypes that might be more responsive to 
specific therapies. Furthermore, evidence of important 
long- term effects in survivors of ARDS is growing, driv-
ing the need for research strategies to study how these 
effects could be mitigated.
This Primer on adult and paediatric ARDS considers 
the epidemiology of ARDS from a global perspective, 
mechanisms of lung endothelial and alveolar epithelial 
injury (including experimental and clinical studies) 
and optimal approaches to diagnosis with a focus on 
screening, early recognition and evaluation for infectious 
and non-infectious causes. We also discuss manage-
ment strategies, including mechanical ventilation, 
fluids and rescue therapies for severe ARDS. Finally, we 
describe quality of life (QOL) after recovery from ARDS. 
Throughout the Primer, the differences between adult 
and paediatric ARDS are considered.
Epidemiology
Adults
A well- designed, prospective analysis of the incidence 
of ARDS in the United States was carried out in a 
population- based cohort study of 21 hospitals in King 
County, Washington, from April 1999 to July 2000, 
focused primarily on adults4. The investigators used a 
validated screening protocol to identify patients with 
ARDS (defined as a partial pressure of arterial oxygen 
(PaO2) to fraction of inspired oxygen (FiO2) ratio (PaO2/
FiO2) of <300 mmHg and bilateral chest radiographic 
opacities without evidence of left- sided heart failure). On 
the basis of these data, the authors estimated an annual 
incidence of 190,000 cases of ARDS in the United States 
with a hospital mortality of 38.5%. Subsequently, the 
LUNG- SAFE study provided valuable data in a cross- 
sectional analysis of 29,144 patients in 50 countries dur-
ing the winter of 2014 (ref.5); in this study, the prevalence 
of ARDS in patients in intensive care was 10%, and ARDS 
was identified in 23% of all ventilated patients. A detailed 
review of ARDS incidence and time- related changes in 
epidemiological factors has been recently published6.
The LUNG- SAFE study also reported that hospi-
tal mortality was 34.9% for patients with mild ARDS, 
40% for those with moderate ARDS and 46.1% for those 
with severe ARDS (Berlin criteria3; Box 1). However, 
it remains unclear how much of the reported mortal-
ity in ARDS can be attributed to ARDS as opposed to 
underlying comorbidities, such as cancer and immuno-
suppression, the associated nonpulmonary organ dys-
function (cardiovascular insufficiency as in septic shock, 
liver dysfunction and renal failure) and/or the older age 
of patients with the condition. For example, a follow- 
up analysis of the LUNG- SAFE study determined that 
21% of patients with ARDS in the study were immuno-
compromised, and hospital mortality was much higher 
in these patients than in non- immunocompromised 
patients (52% versus 36%; P < 0.0001)7.
Importantly, the LUNG- SAFE study revealed that 
clinician recognition of ARDS was low — 51% in mild 
ARDS and only 79% in severe ARDS. Furthermore, 
fewer than two- thirds of patients with ARDS were 
treated with an optimal tidal volume (that is, for 
mechanical ventilation) of <8 ml per kg predicted body 
weight (PBW). Thus, this study confirmed that ARDS 
remains common in critically ill patients and that it is 
under- recognized and under- treated.
Several comorbidities and exposures have been asso-
ciated with increased susceptibility to ARDS, including 
alcohol abuse8, cigarette smoking9,10, air pollution11,12 and 
hypoalbuminaemia13. Diabetes mellitus has been associ-
ated with a lower risk of ARDS development for reasons 
that remain unclear14,15, although data from the LUNG- 
SAFE study showed no association between diabetes 
and the diagnosis of ARDS, developing ARDS or out-
comes of ARDS16. A two- centre clinical study identified 
the major recipient risk factors for developing TRALI, 
including recent liver surgery, chronic alcohol abuse, 
current cigarette smoking, higher peak airway pres-
sure (that is, the highest airway pressure while being 
ventilated) and positive fluid balance17. Transfusion 
risk factors were receipt of whole blood or fresh frozen 
plasma from a female donor and the quantity of human 
leukocyte antigen (HLA) class II antibody or the volume 
concentration of anti- human neutrophil antigen in the 
transfused blood components. There was no risk asso-
ciated with the age of the stored blood. Indeed, elimi-
nating fresh frozen plasma or whole- blood transfusion 
from female donors markedly reduced the incidence 
of TRALI, implicating a role for allogeneic antibodies 
in the pathogenesis of TRALI. In blunt and penetrating 
trauma, the severity and duration of shock, chest injury, 
the number of blood product transfusions, the presence 
of traumatic brain injury and the quantity of crystalloid 
fluids (as a volume expander) can each contribute to the 
risk of developing ARDS18,19.
Studies of the association between ethnicity and ARDS 
outcomes have largely but not uniformly reported higher 
mortality for black and Hispanic patients with ARDS 
than for white patients20,21. In an analysis of patients 
who died with a diagnostic code for ARDS in the United 
States, men had higher average ARDS-related mortal-
ity than women, and black patients had higher mortality 
than white patients, echoing findings from similar 
analyses from prior decades22,23. The aetiology of these 
disparities remains unknown.
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Studies designed to identify genetic factors that might 
contribute to the susceptibility for developing ARDS 
have been reported in the past decade. However, no 
specific loci with genome- wide significance for associ-
ations with ARDS have been identified, probably in part 
because of the phenotypic complexity of ARDS engen-
dered by the different risk factors24. However, other strat-
egies, including candidate gene and pathway analyses, 
have revealed potentially important mechanisms of lung 
injury that seem to be associated with risk of developing 
ARDS and, in some associations, higher mortality25. For 
example, plasma angiopoietin 2 (encoded by ANGPT2) 
is a protein marker and mediator of increased lung vas-
cular permeability; using a quantitative trait loci analy-
sis, five ANGPT2 genetic variants in a population with 
European ancestry have been associated with increased 
levels of plasma angiopoietin 2, and two of the five vari-
ants were associated with increased ARDS risk. No sig-
nificant associations were found with this gene in people 
with African ancestry26.
Children
From a systematic review of 29 paediatric studies27 and 
the PARDIE cross- sectional study of 145 international 
paediatric intensive care units (PICUs)28, the estimated 
population- based incidence of ARDS in children 
(2 weeks to 17 years of age) is 2.2–5.7 per 100,000 person- 
years; most of the children in these studies were <5 years 
of age. ARDS is diagnosed in 2.3–3% of PICU admis-
sions, with an estimated mortality of 17–33%27,28; mor-
tality is lower in highly resourced countries but was not 
associated with age. Over the past two decades, ARDS 
mortality in PICUs has been relatively stable. Although 
the overall number of ARDS- associated deaths is lower 
in children than adults, more productive life years are 
lost from ARDS- related paediatric deaths, as most occur 
in very young patients and ≥40% of these patients were 
previously healthy28.
The major risk factors and pathophysiology of ARDS 
are similar in adults and children28, but paediatric and 
adult ARDS epidemiology have some differences. ARDS 
is more frequent in boys than girls28,29, for reasons that 
are unknown. Over 60% of paediatric ARDS (PARDS) 
is also caused by pneumonia; however, viral infections 
such as respiratory syncytial virus and influenza virus 
more frequently cause life- threatening ARDS in young 
children30. Overall mortality is lowest in children with 
ARDS triggered by lower respiratory infection and high-
est in those with indirect lung injury from sepsis and/or 
shock28. ARDS occurs in only 0.5% of paediatric trauma 
patients, but its associated mortality is 18%31. The inci-
dence, presentation and outcome of TRALI in children 
seems similar to that in adults. A history of prematu-
rity, cancer or immune compromise are risk factors for 
mortality. The severity of hypoxaemia has consistently 
predicted mortality in paediatric cohorts32. In intubated 
children in the PARDIE study, severe ARDS (defined as 
PaO2/FiO2 <100 mmHg) was associated with threefold 
higher mortality than in children with a PaO2/FiO2 of 
100–300 mmHg (ref.28). In addition, a history of cancer 
or haematopoietic stem cell transplantation in paediatric 
patients with ARDS resulted in a mortality of 43% versus 
11% in children without these risk factors in a prospective 
multicentre study33.
Mechanisms/pathophysiology
Here, we focus on the normal and injured lung in ARDS, 
the pathophysiology of ARDS and the mechanisms of 
injury that lead to ARDS, including the contribution 
of ventilator- associated lung injury (VALI). Human lung 
pathology and research on mechanisms of lung injury 
from studies of patients with ARDS are also included.
The normal lung is structured to facilitate carbon 
dioxide excretion and oxygen transfer across the distal 
alveolar–capillary unit (fig. 1). The selective barrier to 
fluid and solutes in the uninjured lung is established 
by a single- layer lining of endothelial cells linked by 
plasma membrane structures, including adherens and 
tight junctions34. The vast surface of the alveolar epithe-
lium is lined by flat alveolar type I (ATI) cells along with 
cuboidal shaped alveolar type II (ATII) cells, forming a 
very tight barrier that restricts even the passage of small 
solutes but allows diffusion of carbon dioxide and oxy-
gen. The ATII cells secrete surfactant, the critical fac-
tor that reduces surface tension, enabling the alveoli to 
remain open and facilitating gas exchange. Both ATI and 
ATII cells have the capacity to absorb excess fluid from 
the airspaces by vectorial ion transport, primarily by 
apical sodium channels and basolateral Na+/K+-ATPase 
pumps35. Thus, when alveolar oedema develops, reab-
sorption of the oedematous fluid depends on junctions 
between ATI and ATII cells and intact ion transport 
channels in the epithelial cells. Once the oedematous 
fluid is absorbed into the lung interstitium, the fluid 
can be removed primarily by lymphatics and the lung 
microcirculation. The cellular makeup of the normal 
alveolus includes alveolar macrophages but not poly-
morphonuclear leukocytes (neutrophils), although they 
Box 1 | Definitions of ARDS in adults
2012 Berlin definition3
•	Timing: respiratory failure within 1 week of a known insult or new and/or worsening 
respiratory symptoms
•	Origin: respiratory failure not fully explained by cardiac function or volume overload 
(need objective criterion such as echocardiography to exclude hydrostatic oedema if 
no risk factor is present)
•	Imaging: bilateral opacities on chest radiograph or CT not fully explained by effusion, 
collapse or nodules
•	Oxygenation: acute onset of hypoxaemia defined as PaO2/FiO2 <300 mmHg on at 
least PEEP 5 cmH2O
a
 - PaO2/FiO2 of 201–300 mmHg is mild ARDS
 - PaO2/FiO2 of 101–200 mmHg is moderate ARDS
 - PaO2/FiO2 ≤100 mmHg is severe ARDS
2016 Kigali modificationb (ref.124)
•	Timing and origin: as in the Berlin definition
•	Imaging: bilateral opacities on chest radiography or ultrasonography scan not fully 
explained by effusion, collapse or nodules
•	Oxygenation: SpO2/FiO2 <315; no PEEP requirement
aPEEP may be delivered non-invasively if the criteria are in the mild category. bThe Kigali 
definition was not directly compared with the Berlin definition in the original publication; 
patients in the Kigali study were not receiving mechanical ventilation. ARDS, acute respiratory 
distress syndrome; FiO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; 
PEEP, positive end- expiratory pressure; SpO2, peripheral capillary oxygen saturation.
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can be rapidly recruited from the circulation. Alveolar 
macrophages, neutrophils and other immune effector 
cells, including monocytes and platelets, are critical in 
defence of the normal lung and have key activities 
in acute lung injury.
In ARDS, there is increased permeability to liquid and 
protein across the lung endothelium, which then leads to 
oedema in the lung interstitium. Next, the oedematous 
fluid translocates to the alveoli, often facilitated by injury 
to the normally tight barrier properties of the alveolar 
epithelium. Increased alveolar–capillary permeability to 
fluid, proteins, neutrophils and red blood cells (resulting 
in their accumulation into the alveolar space) is the hall-
mark of ARDS36–38. Arterial hypoxaemia in patients with 
ARDS is caused by ventilation- to-perfusion mismatch as 
well as right- to-left intrapulmonary shunting. In addi-
tion, impaired excretion of carbon dioxide is a major 
component of respiratory failure, resulting in elevated 
minute ventilation that is associated with an increase in 
pulmonary dead space (that is, the volume of a breath 
that does not participate in carbon dioxide excretion). 
Elevation of pulmonary dead space and a decrease in 
respiratory compliance are independent predictors of 
mortality in ARDS39.
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Fig. 1 | The normal alveolus. The alveolar epithelium is a continuous monolayer of alveolar type I (ATI) cells (very thin cells 
that permit gas exchange) and alveolar type II (ATII) cells (which produce surfactant to enable lung expansion with a low 
surface tension); both cells transport ions and fluid from the alveolus to maintain dry airspaces. The intact alveolar epithelium 
is linked by intercellular tight junctions. Tight junctions are responsible for barrier function and regulating the movement of 
fluid and ions across the epithelium and are composed of transmembrane claudins and occludins and cytoplasmic zonula 
occludens (ZO) proteins that anchor tight junctions to the actin cytoskeleton. Alveolar epithelial cells express plasma 
membrane E- cadherin and β- catenin. β- Catenin also functions as a transcriptional cofactor and has a role in cell turnover in 
the subset of ATII cells that function as stem cells during homeostasis80. Endothelial cells serve to regulate the influx of fluid 
and inflammatory cells into the interstitial space and are connected by intercellular junctions comprising tight junctions and 
adherens junctions. Adherens junctions contain vascular endothelial cadherin (VE- cadherin), which mediates cell–cell contact 
through its extracellular domain and has a key role in barrier function. p120–catentin binds to and stabilizes VE- cadherin, 
which is linked to the actin cytoskeleton via α- catenin (α in the figure) and has multiple additional functional interactions56. 
TIE2 acts in concert with vascular endothelial- protein tyrosine phosphatase (VE- PTP), which dephosphorylates VE- cadherin, 
stabilizing it. Normally , transvascular flux of fluid out of the capillary moves water and low- molecular-weight solutes into the 
interstitial space and then into the lymphatics; in health, this fluid does not cross the epithelial barrier. Resident alveolar 
macrophages populate the airspaces, providing host defence. Large numbers of polymorphonuclear leukocytes (PMNs) 
reside in the alveolar capillaries and can be rapidly mobilized to the airspaces in the setting of infection. β, β- catenin;  
BASC, bronchioalveolar stem cell; ENaC, epithelial sodium channel; JAM, junctional adhesion molecule; RBC, red blood cell.
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Pathology
Interstitial and alveolar oedema are key features of dif-
fuse alveolar damage (DAD) in the acute ‘exudative’ 
phase (~7 days) of ARDS (fig. 2). Eosinophilic depo-
sitions termed hyaline membranes are also defining 
features of DAD, the classic histopathological hall-
mark of ARDS40–42. The other findings include alveolar 
haemorrhage, accumulation of white blood cells (usu-
ally predominantly neutrophils), fibrin deposition and 
some areas of alveolar atelectasis (collapse). After the 
initial exudative phase, ATII cell hyperplasia follows 
in a ‘proliferative’ phase that can last >3 weeks in sur-
vivors; interstitial fibrosis can also occur in this phase. 
The original description of DAD was based heavily on 
analyses of lungs of patients dying with oxygen toxicity, 
although similar histological changes were identified 
in lungs from patients with a variety of conditions that 
underlie ARDS40. Recent reports reveal that DAD is 
present in only a subset of patients with clinical ARDS, 
and pathological heterogeneity is evident41–44. For exam-
ple, one study carried out over two decades (1991–2010) 
on post- mortem samples reported that 45% of patients 
who met the Berlin criteria for ARDS had DAD, whereas 
the other 55% had alveolar inflammation consistent 
with acute pneumonia with infiltration of neutrophils 
in the alveoli and distal bronchioles44. Importantly, this 
study also found that the incidence of DAD declined in 
the decade after lung- protective ventilation was imple-
mented. Recent reports also indicate key temporal fea-
tures of histological progression, identify the association 
of DAD with severity of ARDS and provide evidence that 
the first 7 days after onset represent a critical window for 
potential therapeutic intervention43,44. In addition, one 
meta- analysis of open lung biopsy samples in patients 
with ARDS found that DAD was present in only 48% of 
the patients and was associated with a higher mortality45. 
Neither the severity of hypoxaemia nor the sequential 
organ failure assessment score were different in patients 
with or without DAD on lung biopsy.
Classic electron microscopic analyses demonstrate 
that alterations in endothelial and epithelial cells are 
critical features of acute alveolar injury in ARDS37,46. 
For example, early involvement of ATI cells is frequently 
dramatic and includes focal epithelial destruction and 
denudation of the alveolar basement membrane40,46. By 
contrast, alveolar endothelial cells are usually morpho-
logically preserved and the endothelial lining is contin-
uous, demonstrating that even ultrastructural analyses 
cannot precisely detect abnormalities in the normal 
barrier properties that regulate fluid and protein flux 
across the lung capillaries37. Epithelial cell necrosis is 
usually described in the exudative phase42,47, although 
evidence for apoptosis has also been reported48. Early 
epithelial injury is followed rapidly by ATII cell prolifer-
ation37,40,43,47. Injured but intact alveolar epithelial cells 
seem to drive release of pro- coagulant factors and intra- 
alveolar fibrin deposition49,50, which is also deposited 
adjacent to endothelial cells in injured alveoli37,40,47.
Endothelial damage
The nature of endothelial cell alteration in clinical 
ARDS is incompletely understood. Endothelial ‘damage’ 
and ‘injury’ are commonly described, and recent evi-
dence suggests that apoptosis36 and alternative cell 
death pathways such as pyroptosis51 might be involved. 
Conceptually, an increase in lung vascular perme-
ability can occur because of a functional breakdown in 
endothelial junctions or by death of endothelial cells. 
Ultrastructural alterations of alveolar endothelial 
cells are frequently subtle compared with the dramatic 
epithelial cell disruption observed in autopsy analysis37 
(fig.  2), suggesting functional barrier impairment. 
Experimental evidence has shown that endothelial cell 
activation can occur, induced by inflammatory signals 
from microorganisms (including lipopolysaccharide 
and other toxins) and lung white blood cells in response 
to pathogens (as in pneumonia or nonpulmonary 
sepsis), injury from aspiration syndromes, ischaemia–
reperfusion (as in trauma- induced shock) or blood 
a
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5 μm
Fig. 2 | Microscopic findings in lung tissue in patients with ARDS. In acute respiratory 
distress syndrome (ARDS), features of diffuse alveolar damage (DAD), such as in the 
acute ‘exudative’ phase (~7 days) (panel a), are typically followed by alveolar type II (ATII) 
cell hyperplasia and interstitial fibrosis in a ‘proliferative’ phase. Eosinophilic depositions 
termed hyaline membranes are defining features of DAD (pink structure lining the 
central alveolus, indicated by the arrowhead in panel b) are defining features of DAD. 
Leukocytes are embedded in the hyaline membranes (arrows in panel b). Electron 
microscopic analyses (panel c) demonstrate that alterations in endothelial and epithelial 
cells are critical features of acute alveolar injury in ARDS37,46. Focal epithelial destruction 
of alveolar type I (ATI) cells and denudation of the alveolar basement membrane occur 
early in ARDS, whereas endothelial continuity is preserved with modest alterations in 
most cases. The pattern shown in panel c was identified in the lungs of a patient with 
indirect acute lung injury resulting from sepsis37,46. A , alveolar space; BM, basement 
membrane; C, capillary ; EC, erythrocyte; EN, endothelial cell; HM, hyaline membrane;  
LC, leukocyte. Reprinted with permission of the American Thoracic Society. Copyright  
© 2019 American Thoracic Society. Matthay , M. A. & Zimmerman, G. A. (2005) Acute lung 
injury and the acute respiratory distress syndrome: four decades of inquiry into 
pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. 33, 319–327.  
The American Journal of Respiratory and Critical Care Medicine is an official journal  
of the American Thoracic Society.
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product transfusions as in TRALI36. Endothelial cell 
activation may result in mediator generation (such as 
angio poietin 2) and leukocyte accumulation (accompa-
nied by upregulation of P- selectin and E- selectin (cell 
adhesion molecules) in the lung microvessels, especially 
in the post- capillary venules)36. Platelet and neutrophil 
deposition characteristically occur, often as neutrophil– 
platelet aggregates (fig. 3), as a result of endothelial 
cell activation. Neutrophils and platelets seem to play 
a synergistic role in causing an increase in lung vas-
cular permeability to protein (see below). Endothelial 
disruption can also be caused by pathogens and their 
toxins; endogenous danger- associated molecular 
patterns; barrier- destabilizing factors generated by 
alveolar macrophages, circulating leukocytes and plate-
lets; and pro- inflammatory signalling molecules such 
as tumour necrosis factor (TNF), the inflammasome 
product IL-1β, angiopoietin 2, vascular endothelial 
growth factor, platelet- activating factor and others36. 
Increased systemic vascular permeability frequently also 
occurs, often contributing to hypovolaemia and multiple 
organ failure.
Mechanistic examination of disrupted endothe-
lial barriers has required experimental models. An 
extremely informative large- animal preparation demon-
strated that clinically relevant insults, including intra-
venous bacteria, lipopolysaccharide and microemboli, 
cause an increase in lung endothelial permeability and 
filtration and that there are different responses to these 
insults by the endothelial and epithelial barriers52,53. 
Although the duration of increased lung endothelial per-
meability induced by specific insults in clinical ARDS is 
unknown, this model and more recent studies in mice 
suggest that it can persist for many hours to weeks52–54. In 
experimental models of influenza pneumonia, for exam-
ple, the persistent duration of increased lung vascular 
permeability is associated with lung injury and slow 
recovery54. More precise understanding of the duration 
of barrier disruption may influence the timing of admin-
istration of candidate therapeutics aimed at reducing 
vascular permeability.
VE- cadherin disruption. Studies using cultured 
endothelium and murine models indicate that homo-
philic calcium- dependent vascular endothelial cadherin 
(VE- cadherin) bonds between adjacent endothelial cells 
are critical for basal lung microvascular integrity and that 
their ‘loosening’ is central in increased alveolar–capillary 
permeability in inflammatory acute lung injury36. VE- 
cadherin and TIE2, an endothelial receptor kinase, act in 
concert to establish junctional integrity and are regulated 
by vascular endothelial- protein tyrosine phosphatase 
(VE- PTP; also known as receptor- type tyrosine- protein 
phosphatase β). Genetic or pharmacological manip-
ulation of the molecular interactions and activities of 
VE- cadherin, TIE2 and VE- PTP alters alveolar leak in a 
complex fashion in mice36,55. VE- cadherin function and 
adherens junction stability are also regulated by cytoskel-
etal interactions, small GTPases and other intracellular 
modulators, multiple molecular interactions (including 
associations with catenins, plakoglobin and VE- PTP) 
and phosphorylation and dephosphorylation events36,56. 
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Fig. 3 | The injured alveolus. A variety of insults (such as acid, viruses, ventilator- 
associated lung injury , hyperoxia or bacteria) can injure the epithelium, either directly or 
by inducing inflammation, which in turn injures the epithelium. Direct injury is inevitably 
exacerbated by a secondary wave of inflammatory injury. Activation of Toll- like receptors 
(not shown) on alveolar type II (ATII) cells and resident macrophages induces the 
secretion of chemokines, which recruit circulating immune cells into the airspaces. 
As neutrophils migrate across the epithelium, they release toxic mediators, including 
proteases, reactive oxygen species (ROS) and neutrophil extracellular traps (NETs), 
which have an important role in host defence but cause endothelial and epithelial injury. 
Monocytes also migrate into the lung and can cause injury , including epithelial cell 
apoptosis via IFNβ- dependent release of tumour necrosis factor (TNF)-related apoptosis- 
inducing ligand (TRAIL), which activates death receptors. Activated platelets form 
aggregates with polymorphonuclear (PMN) leukocytes, which are involved in NET 
formation, and monocyte–platelet aggregates. Red blood cells (RBCs) release cell- free 
haemoglobin, which exacerbates injury via oxidant- dependent mechanisms. 
Angiopoietin 2 inhibits TIE2-stabilization of vascular endothelial cadherin (VE- cadherin); 
vascular endothelial growth factor and other permeability- promoting agonists also 
destabilize VE- cadherin via dissociation from p120-catenin, resulting in its 
internalization and enhanced paracellular permeability. Additionally , loss of cell–cell 
adhesion in the setting of actomyosin contraction results in the formation of occasional 
gaps between endothelial cells. Epithelial injury also includes wounding of the plasma 
membrane, which can be induced by bacterial pore- forming toxins or mechanical 
stretch, and mitochondrial dysfunction. Together, these effects result in endothelial and 
epithelial permeability , which further facilitate the transmigration of leukocytes and lead 
to the influx of oedematous fluid and RBCs. Airspace filling with oedematous fluid causes 
hypoxaemia, resulting in the need for mechanical ventilation. The vascular injury and 
alveolar oedema contribute to the decreased ability to excrete CO2 (hypercapnia), 
accounting for the elevated pulmonary dead space in acute respiratory distress 
syndrome. In turn, hypoxaemia and hypercapnia impair vectorial sodium transport, 
reducing alveolar oedema clearance. ATI, alveolar type I cell; BASC, bronchioalveolar 
stem cell; ENaC, epithelial sodium channel.
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Destabilizing signals from pathogens or inflammatory 
cells and mediators responding to infectious agents 
induce phosphorylation of VE- cadherin and its inter-
nalization, frequently by altering activity and balance of 
GTPases56. Dissociation of VE- PTP from VE- cadherin is 
required for loosening of endothelial cell junctions and 
inflammatory alveolar protein leak in mice57. Recent 
observations indicate that inflammation- induced weak-
ening of endothelial junctions is a process involving at 
least two steps, including modification of VE- cadherin 
contacts and alterations in the endothelial actomyosin 
system55. Genetic or pharmacological manipulation 
of VE- PTP can alter alveolar endothelial junctions 
via TIE2-dependent influences on the cytoskeleton 
independently of VE- cadherin55.
Although parallel experiments with cultured human 
endothelial cells suggest translational relevance55, 
direct recapitulation of these observations to alveolar 
endothelial barrier disruption in patients with ARDS 
has not been established. Nevertheless, administration 
to mice of an antibody against VE- cadherin resulted in 
intravascular sequestration of neutrophils and plate-
lets, alveolar neutrophil accumulation and pulmonary 
oedema58 — mimicking the histological pattern in clin-
ical ARDS37. Of note, substantial alveolar oedema in 
experimental acute lung injury was not accompanied by 
widespread overt disruption of endothelial cell junctions 
detectable by electron microscopy55, consistent with 
ultrastructural observations of lung tissue from patients 
with ARDS in which the endothelium was found to be 
largely continuous and endothelial cell junctions were, 
for the most part, morphologically intact37. Thus, in 
animal models and human ARDS, changes in para-
cellular permeability to protein seem to occur in the 
absence of dramatic alterations in the morphology of 
the lung endothelium.
Immune cell recruitment to the lung. Re- establishing 
endothelial junctional bonds may mitigate both 
endothelial leak and excessive myeloid leukocyte accu-
mulation in ARDS36. Indeed, genetic replacement of 
VE- cadherin with a fusion construct that prevented 
its internalization in response to inflammatory signals 
greatly reduced alveolar neutrophil accumulation in 
lipopolysaccharide- challenged mice and reduced vas-
cular permeability59. Recent analysis of samples from 
patients and lipopolysaccharide- challenged volunteers 
indicates that synergistic activity of chemokines contrib-
utes to neutrophil recruitment60. Other signalling mol-
ecules are also likely to be involved36. Degranulation of 
neutrophils with release of intracellular enzymes such 
as neutrophil elastase and oxidant products contributes 
to the lung injury36.
Neutrophils in the intravascular and extravascular 
compartments in acute lung injury are often associated 
with platelets (fig. 3), which have intricate thrombo- 
inflammatory activities including the ability to trigger 
deployment of neutrophil extracellular traps (NETs)36. 
NETs correlate with alveolar–capillary and epithelial 
barrier disruption in ARDS and experimental models61. 
NETs are filamentous chromatin fibres complexed with 
neutrophil- derived antimicrobial proteins, generated by 
a process that is not completely defined. NETs probably 
evolved as an innate mechanism for pathogen contain-
ment and clearance but are also involved in inflamma-
tory insults to the lung and other organs, as illustrated 
in a recent experimental and clinical study of acute lung 
injury and ARDS61.
A recent observation suggests that early intravascular 
interactions of platelets with monocytes — which, simi-
lar to neutrophils, accumulate and have complex activi-
ties in acute lung injury — drive development of ARDS 
in individuals at risk62. Intra- alveolar macrophages play 
an important part in releasing chemotactic factors such 
as IL-8 and chemokines such as CC- chemokine ligand 2 
(also known as MCP1) that enhance the recruitment of 
neutrophils and monocytes into the lung, particularly in 
response to acute pulmonary infections.
Epithelial injury and repair
In the early phase of experimental acute lung injury, 
the epithelium is more resistant to injury than the 
endothelium53, but as described above, some degree of 
epithelial injury is characteristic of ARDS. The extent 
of epithelial injury is also an important determinant of 
the severity of ARDS. The epithelium can be injured 
directly, for example, by bacterial products, viruses, acid, 
oxygen toxicity (hyperoxia), hypoxia and mechanical 
forces, or by inflammatory cells or their products, as in 
sepsis, TRALI and pancreatitis (fig. 3).
As with endothelial injury36,57–59, epithelial injury 
includes dissociation of intercellular junctions63,64. 
Release of cell- free haemoglobin from red blood cells 
contributes to paracellular permeability by oxidant- 
dependent mechanisms. On the basis of experimental 
studies, the cyclo- oxygenase inhibitor acetaminophen 
reduces the tyrosine radical that results from oxidation 
of cell- free haemoglobin (Fe4+ oxidation state to Fe3+ 
oxidation state), thereby reducing the potential for lipid 
peroxidation65. In addition, epithelial cell death37 (apop-
totic or necrotic48,66,67) is a key feature of alveolar injury in 
ARDS and can be directly caused by lytic viral infections, 
bacterial toxins, acid, hypoxia, hyperoxia and mechani-
cal stretch68,69. Neutrophil- derived mediators also induce 
epithelial cell death via multiple mechanisms, including 
oxidation of soluble TNF ligand superfamily member 6 
(FasL)70 and NETs71, whereas inflammatory macro-
phages can induce cell death via mechanisms including 
secretion of TNF- related apoptosis- inducing ligand 
(TRAIL)67. Notably, endogenous mechanisms (such as 
syndecan-1-dependent MET–AKT signalling) can limit 
cell death72.
Additionally, plasma membrane wounding without 
cell death (that is, sublethal injury) may result from 
bacterial pore- forming toxins and/or overdistention 
from positive- pressure ventilation with high tidal vol-
umes. A recent study demonstrated that after membrane 
wounding by Staphylococcus aureus toxin, calcium waves 
spread through gap junctions to neighbouring epithelial 
cells, inducing widespread mitochondrial dysfunction 
and loss of barrier integrity without cell death73. Indeed, 
mitochondrial dysfunction is common in lung injury 
and may be induced by various mechanisms, including 
hypercapnia74.
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Repair of the injured epithelium is critical for clin-
ical recovery75. The time frame for epithelial repair 
may be 2–3 days or several weeks. Because ATI cells 
provide >95% of the normal surface area of the alveo-
lar epithelium and facilitate gas exchange, the process 
of generating new ATI cells is critical to the complete 
repair process. However, initially the proliferation of 
ATII cells can provide a provisional epithelial barrier 
before they transdifferentiate into ATI cells (fig. 4). 
Many growth factors contribute to ATII cell prolifer-
ation and, although ATII cells are the default progeni-
tors responsible for creating new alveolar epithelial cells 
through proliferation, in severe injury, alternate progen-
itor cells may be mobilized. These alternate progenitor 
cells include club cells76 (secretory cells that normally 
line the airways), bronchoalveolar stem cells and 
keratin-5-expressing (KRT5+) cells68,77. Expansion of 
KRT5+ epithelial progenitors is driven by HIF–NOTCH 
and fibrocyte growth factor receptor 2 signalling78, with 
ATII cell fate induced by WNT–β- catenin and impeded 
by NOTCH and HIF79 (fig. 5). The mechanisms under-
lying ATII- to-ATI transdifferentiation are less well 
understood, but recent studies have suggested that 
deactivation of WNT–β- catenin is necessary80. Our 
knowledge of the regenerative role of the alternative 
progenitors is mainly based on mouse models of lung 
injury, although there is evidence that some of these 
progenitors exist in humans as well79.
Repair of the alveolar epithelium is regulated by 
crosstalk between multiple alveolar cell types and 
the extracellular matrix. Although injury- inducing, 
immune cells and their mediators may also promote 
epithelial repair81,82. Fibroblasts secrete epithelial 
growth factors and deposit collagen, which, if exces-
sive, can lead to fibrosis. Sublethal epithelial cell injury 
can also be repaired. For example, plasma membrane 
pores can be excised by endocytosis or exocytosis and 
patched by fusion with lipid endomembrane vesicles83. 
Additionally, damaged mitochondria are degraded via 
mitophagy and replaced via biogenesis or mitochondrial 
transfer84. Finally, reassembly of intercellular junctions is 
regulated by multiple mechanisms, including beneficial 
effects from angiopoietin 1 (ref.85) and signals from the 
basement membrane86. The timing of endothelial and 
epithelial repair in various causes of acute lung injury 
has not been systematically worked out. Once epithe-
lial barrier integrity is restored, oedematous fluid can 
be reabsorbed to the interstitium either by paracellular 
pathways or by diffusion through water channels driven 
by an osmotic gradient that is established by active apical 
sodium uptake, in part by the epithelial sodium chan-
nels and sodium transport through the Na+/K+-ATPase 
pumps (fig. 5).
Unfortunately, many endogenous reparative mech-
anisms are specifically inhibited during ARDS. For 
example, influenza virus infects KRT5+ progenitors78. 
Influenza infection, hypoxaemia, hypercapnia and 
other factors downregulate sodium channel and/or 
Na+/K+-ATPase function, resulting in impaired alve-
olar fluid clearance in patients with ARDS35,75,87,88. 
Hypercapnia impairs alveolar epithelial cell prolifer-
ation74. Keratinocyte growth factor, while stimulating 
proliferation, increases the susceptibility of ATII cells 
to influenza virus infection and mortality in mice89. In 
addition, the many biological changes resulting from 
both endothelial and epithelial injury, and culminating 
in protein- rich oedematous fluid, contribute to sur-
factant dysfunction90. Surfactant dysfunction can then 
increase atelectasis, which in turn can increase the risk 
of biophysical injury.
Mechanical VALI
All the mechanisms that injure the lung endothelium 
and epithelium lead to pulmonary oedema with acute 
respiratory failure owing to reduced oxygenation, 
impaired carbon dioxide excretion and decreased lung 
compliance. As described in the original report of ARDS 
in 1967 (ref.1), the use of mechanical ventilation with 
a cb
Fig. 4 | Epithelial cell regeneration in ARDS. Mice in which the alveolar type II (ATII) epithelial cells and all their progeny 
express green fluorescent protein (GFP) (SftpcCreERT2;mTmG mice) were treated with intratracheal lipopolysaccharide to 
induce lung injury. Mice were euthanized 27 days later and lung sections were stained for GFP (green), the alveolar type I 
(ATI) cell marker T1α (purple) and 4′,6-diamidino-2-phenylindole (DAPI; for nuclear staining (blue)). Some ATII cell- derived 
cells (GFP- staining cells in panels a (×40) and c (×40)) expressed ATI markers (T1α- staining cells in panels b (×40) and c), 
as shown by dual GFP- staining and T1α- staining cells (panel c) — indicating transdifferentiation during repair after lung 
injury. Arrowheads indicate nascent ATI cells that transdifferentiated from ATII cells during repair after injury (dual GFP- 
staining and T1α- staining cells). Arrows indicate ATI cells that withstood the initial injury (GFP- negative but T1a- staining 
cells). These experimental data support the notion that ATI cells are damaged during acute lung injury and are then 
replaced by ATII cells that transdifferentiate into ATI cells. Reprinted with permission of the American Thoracic Society. 
Copyright © 2019 American Thoracic Society. Jansing, N. L. et al. (2017) Unbiased quantitation of alveolar type II to alveolar 
type I cell transdifferentiation during repair after lung injury in mice. Am. J. Respir. Cell Mol. Biol. 57, 519–526. The American 
Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
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supplemental oxygen and positive end- expiratory pres-
sure (PEEP) was life- saving in this context. For many 
years, the standard therapy with mechanical ventilation 
support included high tidal volumes (12–15 ml per kg 
PBW). Nevertheless, a potential contribution of high 
tidal volumes and elevated airway pressures to wors-
ening acute lung injury was suggested by preclinical 
studies beginning in 1974 (refs91–93). The clinical impor-
tance of VALI was provided by the ARMA trial in 2000 
(see below, Management), in which lower tidal volume 
and limited airway pressure markedly reduced mortal-
ity in patients with ARDS94. The mechanisms for VALI 
have been established in both experimental and clinical 
studies. High tidal volume and elevated airway pressure 
induce biomechanical inflammatory injury and necro-
sis of the lung endothelium and alveolar epithelium 
that are associated with release of neutrophil products, 
including proteases, oxidants and pro- inflammatory 
cytokines, and a reduction in the capacity of the alveo-
lar epithelium to remove oedematous fluid36,95,96. Clinical 
studies focused on biology and clinical factors have also 
confirmed the injurious effects of high tidal volume in 
patients with ARDS (see below). It should be empha-
sized that it has not been possible to eliminate VALI as 
it can still occur from patient–ventilator dyssynchrony 
and elevated plateau airway pressure (that is, the elevated 
pressures generated by the mechanical ventilator to the 
alveoli), especially in patients with severe lung injury and 
extensive pulmonary oedema.
Insights from clinical studies
With the exception of supportive care therapies such as 
lung- protective ventilation and fluid- conservative ther-
apy (see Management), translating insights from experi-
mental studies in animal models into effective therapies 
for human ARDS has proved challenging. Indeed, the 
search for specific pharmacotherapies that effectively 
treat ARDS has been fruitless, despite decades of promis-
ing preclinical research97. In an attempt to overcome this 
obstacle, investigators have sought to further understand 
the biology of human ARDS through studies of human 
samples obtained from observational and interventional 
clinical studies. These studies from patients with ARDS 
have validated several pathophysiological observations 
from experimental studies, led to the identification of 
promising prognostic biomarkers in humans (Box 2) and 
identified molecular subphenotypes of human ARDS 
that may have therapeutic implications.
Initial studies of ARDS pathogenesis using human 
samples confirmed that the biological mechanisms 
identified in many models are relevant. Important ini-
tial observations included confirmation in humans of 
the fundamental hallmark of ARDS, disruption of the 
alveolar–capillary barrier, by documentation of ele-
vated protein levels in pulmonary oedematous fluid38,98. 
Subsequent studies of biological markers from broncho-
alveolar lavage, pulmonary oedematous fluid or (most 
commonly) plasma (which is more readily available in 
most cases) demonstrated that endothelial injury99–101 
and an exaggerated inflammatory response102,103 are con-
sistent features of human ARDS. Endothelial activation 
in particular seems to occur early in the development of 
Fibroblast
Endothelial
cell
ATII
ATI
Activated platelet
Interstitium
Capillary
RBC
Collagen
Mitochondria
Pro-resolving
macrophage K
+
Na+
ENaC
Na+
K+ Na
+
Na+
KRT5+
GM-CSF
β-catenin
HIF NOTCH
Endothelial
integrity
restored
Restored fluid
and ion
clearance
Junctional
reassembly
Membrane
pores patched
Mitochondrial
biogenesis and transfer
ATII proliferation 
SDF1
MMP14
T
reg
 cell
HB-EGF
KGF
ATII to ATI
transdifferentiation
β-catenin
KGF HGF
Apoptotic
PMN
Cellular
debris
Club cell
Ciliated cell
BASC
Na+/K+-ATPase
WNT
Fig. 5 | The repaired alveolus. Several mechanisms promote endothelial cell 
junctional reassembly. Slit binds to its receptor, ROBO4, stabilizing the adherens 
junctions by promoting the association between p120–catenin and vascular 
endothelial cadherin (VE- cadherin) (not shown). Activated platelets release the  
lipid mediator sphingosine 1-phosphate (S1P), which activates Rho/Rac signalling  
to induce cytoskeletal reorganization that promotes endothelial barrier integrity 
(not shown). The receptor tyrosine kinase TIE2 is bound by its activating ligand, 
angiopoietin 1, which results in actin cytoskeletal reorganization and stability  
of VE- cadherin at the adherens junctions (not shown). To repair the damaged 
epithelium, surviving alveolar type II (ATII) cells replace lost epithelial cells via 
proliferation and differentiation into alveolar type I (ATI) cells. Many growth factors 
promote ATII proliferation, including keratinocyte growth factor (KGF), epidermal 
growth factor (EGF)80, hepatocyte growth factor (HGF) and granulocyte–macrophage 
colony- stimulating factor (GM- CSF); similarly , transcriptional pathways also 
promote ATII proliferation, including the WNT–β- catenin pathway80,82,239 and the 
forkhead box protein M1 (FOXM1) pathway240. Toll- like receptor 4 and hyaluronan 
signalling also contribute241. In severe injury , alternate progenitors (keratin 
5-expressing epithelial progenitors (KRT5+) and club cells) are mobilized to 
proliferate and differentiate into ATII cells. Withdrawal of β- catenin signalling 
induces ATII cells to transdifferentiate into ATI cells80. Fibroblasts and endothelial 
cells (and epithelial cells) secrete epithelial growth factors80,242; for example,  
platelet- derived stromal cell- derived factor 1 (SDF1) stimulates endothelial cells  
to secrete matrix metalloproteinase 14 (MMP14), which cleaves heparin- bound  
EGF (HB- EGF), enabling it to ligate the EGF receptor and stimulate ATII cell 
proliferation242. Membrane pores can be patched and damaged mitochondria  
can be removed by mitophagy. Once the alveolar epithelium is regenerated, 
pro-resolving macrophages clear dead cells and debris and ATII and ATI epithelial 
cells reabsorb oedematous fluid. BASC, bronchioalveolar stem cell; ENaC,  
epithelial sodium channel; PMN, polymorphonuclear; RBC, red blood cell; Treg cell,  
regulatory T cell.
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human ARDS, in some cases predating frank respira-
tory failure104. Lung epithelial injury in human ARDS 
has been identified by measurement of impaired alveolar 
fluid clearance75 and more recently by measurement of 
specific markers of alveolar epithelial cell injury, includ-
ing surfactant protein D105 and the receptor for advanced 
glycation end products (RAGE), a marker of lung epithe-
lial injury and innate immune activation106. Importantly, 
many of these markers of injury have also been linked 
to poor clinical outcomes in ARDS (Box 2), suggesting 
that the severity of the endothelial and epithelial injury 
in humans is a major determinant of clinical outcome107.
Biological samples from interventional clinical trials 
in ARDS have proved to be particularly useful in fur-
thering understanding of ARDS pathogenesis. As one 
example, analysis of plasma inflammatory markers 
from patients enrolled in the seminal trial of low tidal 
volume ventilation for ARDS94 demonstrated that a 
lung- protective ventilation strategy decreased circulat-
ing markers of inflammation (IL-6 and IL-8) compared 
with a traditional high tidal volume strategy108. Analyses 
of plasma levels of RAGE from the same trial confirmed 
that lung- protective ventilation also decreased alveolar 
epithelial cell injury compared with traditional tidal vol-
umes109. Another study reported a reduction in distal air-
space IL-6, TNF and neutrophils in patients treated with 
a lung- protective ventilation strategy110.
Most recently, analyses of biological samples from 
large clinical trials have enabled studies focused on 
heterogeneity in ARDS, specifically on the identification 
of molecular subphenotypes of ARDS that may respond 
differently to therapies. In many other medical disci-
plines, most notably in oncology, the identification of 
discrete molecular subtypes within broader clinical 
syndromes has led to remarkable therapeutic progress 
and a revision of diagnostic paradigms — consider, for 
instance, hormone receptor status in breast cancer. In 
ARDS, biological heterogeneity has long been suspected 
as a potential obstacle to successful development of ther-
apeutics; early descriptions of the syndrome speculated 
whether direct (that is, pulmonary) and indirect (that 
is, nonpulmonary) causes of ARDS, for example, might 
be pathologically distinct2. Supporting this hypothesis, a 
recent analysis of direct and indirect ARDS in two clin-
ical cohorts showed that patients with direct lung injury 
had higher plasma levels of biomarkers of lung epithe-
lial injury (such as RAGE and surfactant protein D), 
whereas patients with indirect lung injury had higher 
plasma levels of biomarkers of endothelial injury and 
inflammation (including angiopoietin 2)111.
An alternative approach to deconvoluting ARDS het-
erogeneity has been the use of unsupervised analytical 
approaches, most prominently latent class analysis, to 
identify subphenotypes within ARDS. This approach 
has now been replicated in analyses of five clinical trials, 
finding strong evidence for two distinct subphenotypes 
of ARDS112–115. Approximately 30% of patients with 
ARDS consistently fall into the so- called hyperinflam-
matory subphenotype, characterized by high plasma lev-
els of inflammatory biomarkers (IL-6, IL-8, soluble TNF 
receptor 1), low protein C and high prevalence of shock 
and metabolic acidosis. By contrast, the so- called hypo- 
inflammatory subphenotype comprises ~70% of patients 
who have lower levels of the inflammatory biomarkers, 
less acidosis and less vasopressor- dependent shock. 
Mortality was higher in the hyperinflammatory sub-
phenotype than in the hypo- inflammatory subphenotype 
in all of the five clinical trials.
In secondary analyses of the completed randomized 
controlled trials, these two ARDS subphenotypes 
responded differently to PEEP, fluid management and, 
of most interest, simvastatin therapy114. Statins have 
been proposed as a treatment for ARDS because of 
their potential anti- inflammatory properties. In a ran-
domized placebo- controlled clinical trial of simvastatin 
in 540 patients with ARDS, there was no effect on mor-
tality116. However, a secondary analysis of the trial data 
revealed that the patients who were classified in the 
hyperinflammatory subphenotype and were treated with 
simvastatin had a significantly higher 28-day survival 
than the hyperinflammatory patients who were treated 
with placebo. There was no difference in 28-day survival 
in the hypo- inflammatory patients treated with simva-
statin or placebo114. If validated in prospective clinical 
studies, this approach suggests that future clinical trials 
targeting patients on the basis of distinct biological sub-
phenotype may be more successful than trials based on a 
clinical syndromic definition. The definitive mechanistic 
differences between these two subphenotypes, including 
whether they are driven by environmental or genetic fac-
tors, remain yet to be identified. The goal of integrating 
the biological and clinical variables of greatest value for 
Box 2 | Selected biomarkers associated with human ARDS
Epithelial markers (principal source)
•	Receptor for advanced glycation end products (alveolar epithelial type 1 cells)
•	Surfactant protein D (alveolar epithelial type 2 cells)
•	Club cell 16 (airway epithelial cells)
Endothelial markers (principal source)
•	von Willebrand factor (endothelium and platelets)
•	Angiopoietin 2 (endothelium and platelets)
•	Intercellular adhesion molecule 1 (endothelium, epithelium and macrophages)
•	Syndecan (endothelial glycocalyx)
•	Endocan (endothelium)
Inflammatory markers (principal source)
•	IL-6 (monocytes, macrophages, neutrophils and alveolar epithelium)
•	IL-8 (monocytes, macrophages, endothelium and alveolar epithelium)
•	Soluble tumour necrosis factor receptor 1 (alveolar epithelial type 1 and type 2 cells 
and macrophages)
•	IL-1β, IL-1 R antagonist (monocytes, macrophages and alveolar epithelium)
•	Neutrophil extracellular traps (neutrophils)
Coagulation and fibrinolysis markers (principal source)
•	Protein C (plasma)
•	Plasminogen activator inhibitor 1 (endothelium and macrophages)
Apoptosis markers (principal source)
•	FAS and FasL (endothelium, alveolar epithelium and inflammatory cells)
Selected on the basis of several clinical studies that were focused on the pathogenesis and 
prognosis of ARDS. ARDS, acute respiratory distress syndrome; FAS, tumour necrosis factor 
receptor superfamily member 6; FasL, tumour necrosis factor ligand superfamily member 6.
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predictive and prognostic enrichment in clinical trials 
will require more research.
In addition, research to study transcriptomics in both 
observational and clinical trials of ARDS will be needed 
to identify patterns that may help segregate pathways of 
lung and systemic injury. One recent study of an obser-
vational cohort of 210 patients with sepsis- related ARDS 
used microarray analysis to compare whole- blood gene 
expression in patients stratified into ‘reactive’ (61% of 
the cohort) and ‘uninflamed’ subphenotypes of ARDS117. 
In those with a reactive subphenotype, genes associated 
with neutrophils were more expressed than in those with 
the uninflamed subphenotype. Pathway analysis in the 
reactive patient group showed enrichment of oxida-
tive phosphorylation, mitochondrial dysfunction and 
cholesterol metabolism whereas the uninflamed group 
showed patterns associated with cell proliferation. 
Future studies that include RNA- sequencing will reduce 
bias compared with the microarray approach, and stud-
ies that include samples from both the blood and distal 
airspaces should provide insight into the pulmonary ver-
sus systemic pathways that contribute to lung injury118. 
Studies that link gene expression to protein expres-
sion will be helpful, as illustrated in one prior study 
of sepsis-related ARDS119.
Diagnosis, screening and prevention
Most patients who present with the early phase of acute 
lung injury complain of feeling short of breath. If pneu-
monia is the cause, they will often have a cough that pro-
duces purulent sputum. On physical examination, they 
appear to be in moderate or severe respiratory distress 
with an elevated respiratory rate and tachycardia and 
they usually are working harder than normal to breathe. 
Hypoxaemia may manifest with evidence of cyanosis in 
their fingernail beds. Oxygen saturation on room air will 
be decreased. Respiratory deterioration in ARDS may be 
hyper- acute (for example, in the case of TRALI, in which 
respiratory failure is often fulminant) or may develop 
slowly over a period of hours to days.
Diagnosis
Adults. Even after the development and refinement 
of the Berlin diagnostic criteria (Box 1), several aspects of 
diagnosing ARDS remain challenging. Chest radiograph 
interpretation is inherently (at present) subjective, and 
investigators studying chest radiograph interpretation 
in ARDS in particular have demonstrated subopti-
mal inter- rater reliability120. Similarly, differentiation 
of ARDS from hydrostatic pulmonary oedema due to 
heart failure and/or volume overload can be difficult in 
critically ill patients (fig. 6). The 1992 consensus defini-
tion of ARDS included a requirement that the pulmo-
nary arterial wedge pressure be <18 mmHg if measured; 
however, pulmonary arterial catheters are now rarely 
used in this setting, primarily because a randomized trial 
showed no clinical benefit of their use compared with 
central venous catheters in 1,000 patients with ARDS121. 
The Berlin definition of ARDS recommends the use of 
echocardiography to assess cardiac function if no clear 
ARDS risk factor is identified. Other tests that may be 
useful in this distinction include measurement of brain 
natriuretic peptide (BNP; which, if elevated, suggests 
cardiac insufficiency), assessment of the vascular pedicle 
width on chest radiograph (which suggests intravascular 
volume overload) and/or measurement of the ratio of 
protein in pulmonary oedema fluid to plasma (which, if 
<0.65, suggests elevated lung vascular pressures as in car-
diogenic pulmonary oedema versus a ratio >0.65, which 
suggests increased alveolar–capillary permeability as in 
ARDS), although this test is less widely available122,123. 
These complexities may contribute to persistent under- 
recognition of ARDS by clinicians. In under- resourced 
settings without ready access to advanced diagnostic 
modalities and therapies, diagnosis of ARDS can be 
further hindered. Thus, in 2016, investigators proposed 
alternative criteria for ARDS diagnosis in the absence of 
chest radiography, mechanical ventilation and/or blood 
gas measurements — the so- called Kigali modification 
of the Berlin criteria124 (Box 1).
Another important aspect of diagnosing ARDS 
depends on excluding mimics of the syndrome that may 
require specific treatment. Such mimics include acute 
eosinophilic pneumonia, diffuse alveolar haemor rhage, 
acute interstitial pneumonia, cryptogenic organizing 
pneumonia, acute exacerbations of idiopathic pul-
monary fibrosis and acute heart failure (fig. 6). ARDS 
occurs in the setting of an underlying risk factor (for 
example, sepsis, pneumonia or severe trauma); identi-
fication of this risk factor is required to ensure that the 
patient actually has ARDS and not an ARDS mimic 
and because treatment of the underlying risk factor 
is vitally important for patient care. If no ARDS risk 
factor is readily apparent, suspicion for an ARDS mimic 
should increase. In this case, bronchoscopy with bron-
choalveolar lavage and cell counts and differential 
can be helpful diagnostically. If the aetiology remains 
unclear after bronchoscopy, lung biopsy (thoraco-
scopic or, less commonly, open) may be considered if 
results would change patient management. Studies on 
the diagnostic yield of lung biopsy samples in these 
settings report varying diagnostic yields (60–84%) and 
substantial morbidity and mortality; a recent review 
a b
Fig. 6 | Distinguishing ARDS on radiography. Similarities in the chest radiographs from 
a patient with acute respiratory distress syndrome (ARDS) from influenza pneumonia 
(panel a) and a patient with pulmonary oedema due to cardiac failure (panel b) reflect the 
difficulty in identifying ARDS. In both cases, diffuse bilateral parenchymal opacities are 
consistent with alveolar filling. The cardiac silhouette (panel b) is slightly more globular, 
consistent with heart failure; however, this feature is not reliable for distinguishing ARDS 
from cardiogenic pulmonary oedema.
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provides a thoughtful algorithm for when to consider 
lung biopsy in ARDS125.
Children. Given the differences in ARDS between 
adults and children, the international Pediatric Acute 
Lung Injury Consensus Conference (PALICC) defined 
criteria for PARDS126 (Box 3). There are major differences 
between the PALICC PARDS definition and the adult 
American–European Consensus Conference or Berlin 
definitions. In PARDS, as in the Kigali modification of 
the Berlin definition, the peripheral capillary oxygen 
saturation (SpO2) to FiO2 ratio is used when arterial 
PaO2 is not available; however, lung ultrasonography 
is not incorporated into the diagnostic criteria for 
PARDS126. The presence of bilateral radiographic opaci-
ties, used to distinguish diffuse lung disease but difficult 
to detect with accuracy, is not required for PARDS126. 
Hypoxia assessment for intubated children requires 
adjustment for level of respiratory support using mean 
airway pressure (MAP) by calculating an oxygenation 
index126 (Box 3).
Neonates outside of the perinatal period were 
included in the PARDS definition, and additional cri-
teria for diagnosing PARDS in children with paediat-
ric cyanotic congenital heart disease and chronic lung 
disease were proposed126. The PARDS definition was 
more inclusive, aiming to diagnose ARDS in the early 
stages. Children diagnosed with PARDS using the 
PALICC criteria had 24% mortality if they also met 
the Berlin criteria, versus <8.5% if they did not28. If the 
patients were treated with noninvasive ventilation and 
using the oxygen saturation (SaO2) to FiO2 ratio for diag-
nosis with unilateral infiltrates, the mortality was 7%. 
Neonatal lung disease experts have proposed a consen-
sus definition for neonatal ARDS called the Montreaux 
definition127, which is proposed for neonates from 
birth to 44 weeks post- menstrual age (4 weeks if born 
at term). Children with respiratory distress syndrome 
from prematurity and surfactant deficiency and those 
with transient tachypnoea of the newborn or congen-
ital anomalies causing the respiratory condition are 
excluded. The Montreaux definition is similar to the 
PALICC PARDS definition (Box 3) in terms of timing 
and uses PALICC cut- offs for oxygenation index but 
requires arterial or transcutaneous oxygen tension val-
ues rather than SpO2. Furthermore, determining origin 
of oedema requires use of echocardiography to verify 
absence of congenital heart disease as a contributor, and 
imaging must show diffuse bilateral infiltrates or com-
plete lung opacification. Validation of these definitions 
is needed in large prospective cohorts with autopsy and 
pathophysiological correlates to differentiate ARDS 
from other causes of hypoxaemia.
Diagnostic work- up
A comprehensive history and physical examination, 
radiographic imaging (including a chest radiograph 
and sometimes abdominal imaging) and laboratory 
tests are required to search for a clinical risk factor that 
is associated with ARDS. Because bacterial and viral 
respiratory infections of the lung (including secondary 
bacterial infections after an initial viral infection) are the 
most common risk factors associated with ARDS, this 
section focuses on pulmonary infections as part of the 
diagnostic work- up. The typical diagnostic approach 
includes blood cultures and microscopic examination 
and culture of respiratory specimens.
When evaluating a patient with suspected ARDS for 
the likely causative pathogen or pathogens, several fac-
tors should be taken into consideration. Whether infec-
tion is community- acquired or healthcare- associated is 
an important determinant of the potential pathogens 
(fig. 7). Other important factors include age and the 
presence of comorbid conditions, exposure history and 
vaccination status. In addition to commonly isolated 
organisms, physicians should consider other uncommon 
but important pathogens that are linked to travel or res-
idence in certain geographic distributions or to specific 
exposures. Examples include the Middle East respiratory 
syndrome coronavirus (MERS- CoV), avian influenza 
H5N1 and H7N9 viruses, hantavirus, human adeno-
virus subtype-55 (HAdV-55), Plasmodium species, 
Blastomyces dermatitidis, Coxiella burnetti, coccidioi-
domycosis, histoplasmosis, Mycobacterium tuberculosis 
and Yersinia pestis (fig. 7). For instance, patients who 
have travelled to Saudi Arabia and have been exposed 
to camels have a higher risk of developing MERS- CoV; 
patients who live in the central valley of California have 
a higher risk of developing coccidioidomycosis.
In patients without an identified pathogen using tra-
ditional microbiological tests of tracheal aspirate or spu-
tum examination, the use of bronchoalveolar lavage leads 
to identification of pathogens in some but not all patients. 
The percentage of patients with ARDS with no identified 
organisms, even with bronchoalveolar lavage examina-
tion, remains high (>50–60%)128. Pathogens, or their 
markers (such as DNA), can also enter the bloodstream, 
which may in the future enable pathogen identification 
without the need for bronchoalveolar lavage129.
Nucleic acid detection tests, such as PCR, are available 
to detect multiple common viruses and bacteria such as 
Mycoplasma spp., Chlamydia pneumoniae and Bordetella 
pertussis. PCR panels for identifying and quanti fying 
Box 3 | PALICC criteria for PARDS
•	Age: exclude patients with perinatal- related lung disease
•	Timing: respiratory failure within 1 week of known insult
•	Origin: respiratory failure not fully explained by cardiac function or fluid overload
•	Imaging: new unilateral or bilateral infiltrate or infiltrates consistent with acute 
pulmonary parenchymal disease
•	Oxygenation: invasive mechanical ventilation severity stratification is as follows:
 - OI ≥4 to <8 or OSI ≥5 to <7.5 is mild PARDS
 - OI ≥8 to <16 or OSI ≥7.5 to <12.3 is moderate PARDS
 - OI ≥16 or OSI ≥12.3 is severe PARDS
•	Oxygenation: noninvasive mechanical ventilation severity (not stratified) is as follows:
 - Full face-mask bi-level ventilation or CPAP ≥5 cmH2O and
 - PaO2/FiO2 ≤300 or SaO2/FiO2 ≤264
CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; MAP, mean airway 
pressure; OI, oxygenation index (which is (MAP × FiO2 × 100)/PaO2); OSI, oxygen saturation 
index (which is (MAP × FiO2 × 100)/SpO2, with SpO2 ≤97% required for assessment); PALICC, 
Pediatric Acute Lung Injury Consensus Conference; PARDS, paediatric acute respiratory 
distress syndrome; PaO2, partial pressure of arterial oxygen; SaO2, oxygen saturation; SpO2, 
peripheral capillary oxygen saturation.
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common bacteria such as S. aureus and Streptococcus 
pneumoniae are also becoming available. However, estab-
lishing causation remains a challenge because these tests 
do not differentiate pathogens from colonizers, nor do 
they distinguish primary pathogens that trigger ARDS 
from pathogens that may have invaded secondarily. 
In addition, the variable availability of PCR testing, local 
testing practices and specimen timing, quality and type 
(sputum versus bronchoalveolar lavage) all influence 
pathogen identification, further influencing reported 
epidemiology.
Next- generation sequencing is likely to become 
more common to detect pathogens and may change 
our understanding of ARDS epidemiology130. Increased 
test sensitivity will identify pathogens that frequently 
colonize the respiratory tract in patients with pneu-
monia and ARDS128,131. However, physicians need to 
consider pre- test probability in interpreting these 
results; for example, viruses such as respiratory syncytial 
virus and human metapneumovirus are more likely 
to cause ARDS in young children, elderly individuals 
and immunosuppressed individuals than in those who 
are immunocompetent30,131,132. Finally, it is always impor-
tant to consider nonpulmonary causes of ARDS, including 
intra- abdominal infections.
Screening for and predicting ARDS
At present, there is neither strong evidence nor consensus 
regarding whether or how patients should be screened for 
ARDS. ARDS occurs only in a minority of patients with a 
risk factor, making screening challenging133. Furthermore, 
ARDS development often occurs quite quickly, with the 
majority of patients who go on to develop ARDS doing so 
in the first 12–48 hours of hospitalization104,133–135.
Clinical scores have been developed to predict ARDS 
in at- risk patients, most prominently the Lung Injury 
Prediction Score (LIPS)136. The LIPS synthesizes avail-
able clinical data that include predisposing risk factors, 
comorbidities and acute physiological variables to gen-
erate a risk score; higher scores indicate greater risk 
of developing ARDS. The negative predictive value of 
the LIPS is high, but the positive predictive value even 
in the original description was low (18% for a LIPS ≥4); 
a clinical trial using this LIPS cut- off as an enrolment 
criterion found an even lower positive predictive value of 
10%137. An alternative approach is the Early Acute Lung 
Injury (EALI) score, which aims to identify patients with 
incipient lung injury before frank ARDS138,139. This sim-
pler score was developed from analysis of patients with 
acute bilateral radiographic opacities and is comprised 
of three variables: level of supplemental oxygen required; 
tachypnoea; and presence of immune suppression. In 
comparison with LIPS, the negative predictive value of 
the EALI score was again high, but the positive predic-
tive value was better (53%). Although the LIPS and EALI 
scores have not been rigorously tested in children, the 
PARDIE study showed that many children with mild 
disease will progress to meeting the Berlin criteria within 
3 days of being diagnosed with PARDS.
Biomarkers have also been evaluated as potential 
ARDS predictive instruments. For example, levels of 
von Willebrand Factor, a marker of endothelial injury, 
were predictive of development of ARDS in a small study 
of patients with nonpulmonary sepsis100 and in a more 
recent, larger study in patients with severe trauma140. 
Angiopoietin 2 and IL-8 were also found to be elevated in 
critically ill patients before ARDS development104. In this 
analysis, angiopoietin 2 improved the positive predictive 
value of the LIPS. The soluble form of RAGE has been 
reported to be predictive of ARDS development in chil-
dren undergoing cardiac surgery141 and more recently in 
critically ill patients at risk of ARDS142, although other 
reports have not found soluble RAGE to be predictive 
in this setting104. These data provide important evi-
dence that endothelial and lung epithelial injury are well 
underway before patients fulfil ARDS diagnostic criteria; 
however, as the biomarkers in question are not clinically 
available, their use is restricted to research settings.
Prevention and early treatment
For decades, clinicians and researchers have wondered 
whether preventive therapies implemented early in the 
progression of acute lung injury, before patients meet 
ARDS diagnostic criteria, could improve clinical out-
comes. Unfortunately, most trials focused on preven-
tion using pharmacotherapies have met disappointing 
results. In the earliest trials to test this approach, corti-
costeroids were evaluated for ARDS prevention in at- risk 
patients, with no evidence of benefit143,144. More recently, 
a phase IIb clinical trial testing aspirin as a preventive 
therapy in at- risk patients was negative137, although 
a subsequent re- analysis of the data raised interesting 
issues62. A smaller phase IIa trial of aerosolized budeso-
nide (a corticosteroid) and formoterol (a long- acting 
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Fig. 7 | Common respiratory pathogens in ARDS and associated demographic 
features and comorbidities. Common community- acquired and hospital- acquired 
pathogens that cause pneumonia should always be considered in patients with 
suspected acute respiratory distress syndrome (ARDS). Some organisms such as 
Streptococcus pneumoniae are more common as community- acquired infections 
whereas Pseudomonas aeruginosa is more common as a hospital- acquired infection in 
ARDS. Enterobacteriaceae include Klebsiella pneumoniae, Escherichia coli and 
Enterobacter species. The group ‘other respiratory viruses’ includes parainfluenza virus, 
human metapneumovirus virus, respiratory syncytial virus, rhinovirus, coronaviruses and 
adenovirus. A detailed, expanded version of this figure can be found in Supplementary 
Fig. 1. COPD, chronic obstructive pulmonary disease.
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β2-agonist that may improve alveolar fluid clearance) 
demonstrated improved oxygenation and a decreased 
rate of progression to ARDS in the treatment group, 
although baseline randomization imbalances may have 
affected this result145. In contrast to these results with 
pharmacotherapy trials, studies evaluating the use of 
low tidal volume ventilation in mechanically ventilated 
patients without ARDS have provided more evidence of 
benefit146,147, but a recent large clinical trial comparing 
low with intermediate tidal volumes in patients with-
out ARDS was negative148. Several studies have noted 
reductions in nosocomial ARDS incidence thought to 
be associated with improvements in supportive care149,150.
Although true prevention trials have been challeng-
ing to conduct because of the rapid development and 
low incidence of ARDS, an alternative approach has 
been to test the value of early treatment in patients with 
incipient acute hypoxaemic respiratory failure, which 
in many cases progresses to ARDS. A French trial illus-
trated the potential value of this approach, comparing 
high- flow nasal cannula to noninvasive ventilation and 
face- mask oxygen in 310 non- intubated patients with a 
PaO2/FiO2 <300 mmHg (ref.151). The majority of patients 
(64%) had pneumonia, and 79% had bilateral radio-
graphic opacities on chest radiography, indicating that 
they likely had early ARDS. High- flow nasal cannula did 
not affect the primary outcome of endotracheal intuba-
tion but did lead to statistically significantly lower mor-
tality than both noninvasive ventilation (P = 0.006) and 
face- mask oxygenation (P = 0.046). This trial may serve 
as a useful paradigm for future early treatment trials in 
selected patient populations, especially emphasizing 
the opportunity to identify patients in the early phase of 
acute lung injury before endotracheal intubation (fig. 8). 
Of note, the potential benefit of high- flow nasal cannula 
may not be generalizable across all patients in intensive 
care. A recent randomized controlled study showed that 
high- flow oxygen therapy did not significantly decrease 
28-day mortality compared with standard oxygen ther-
apy among critically ill immunocompromised patients 
with acute respiratory failure152.
Management
Management of ARDS focuses on the diagnosis and 
treatment of infections, respiratory support (including 
oxygen supplementation and positive- pressure venti-
lation), careful fluid management (which is especially 
important if the patient is in shock) and general support-
ive measures such as nutritional supplementation. The 
details of appropriate antimicrobial therapy for the many 
pulmonary infections that can cause ARDS are beyond 
the scope of this Primer. However, as general principles, 
when prescribing antimicrobial therapies targeting lung 
infections, clinicians should consider antibiotic potency 
(low minimal inhibitory concentration (MIC) values 
against the organism), likelihood of antimicrobial resist-
ance, ability of the antibiotic to penetrate lung tissue and 
speed of lung penetration153. Continuous infusions can 
increase the amount of time antibiotics exceed the MIC 
and have been shown to improve clinical outcomes with 
certain antibiotics154. In addition, some patients will have 
infections that require surgical intervention, including 
localized or diffuse peritonitis155, soft tissue infections 
(including necrotizing fasciitis) and empyema, which 
requires chest tube drainage of the pleural space.
Respiratory support
Historically, the focus of mechanical ventilation in 
acute respiratory failure has been to maintain adequate 
oxygenation and carbon dioxide elimination. Several 
preclinical studies indicated that the common clinical 
practice of using relatively high tidal volumes and ele-
vated airway pressures for ARDS patients might exacer-
bate the degree of lung injury36. As mentioned above, in 
2000, investigators supported by the US National Heart 
Lung and Blood Institute ARDS Network completed a 
randomized phase III clinical trial in which a tidal vol-
ume of 6 ml per kg PBW, compared with the more com-
mon higher tidal volume of 12 ml per kg PBW, improved 
survival, shortened duration of mechanical ventilation, 
attenuated systemic inflammation and accelerated 
recovery of extra- pulmonary organ failures94, and the 
biologic findings were reported in other studies105,108–110. 
Thus, with the discovery of the major role that mechan-
ical forces play in the pathogenesis of lung injury, opti-
mizing ventilator support to minimize VALI has become 
central to clinical management of ARDS, leading to the 
concept of lung- protective ventilation.
Tidal volume. The ARDS lung is non-uniformly aera-
ted, with nonaerated areas predominantly in gravity- 
 dependent regions, owing to the superimposed weight of 
inflammatory pulmonary oedematous fluid156. Aerated 
a b
Fig. 8 | Identifying patients with early acute lung injury before progression to ARDS 
by the Berlin criteria. Anterior–posterior chest radiographs in a critically ill 48-year- old 
man who presented to the emergency department with worsening dyspnoea, 
hypoxaemia (oxygen saturation of 70% on room air) and a 3-day history of fever, chills 
and a productive cough. He also had acute kidney failure with severe oliguria and a 
serum creatinine of 6.2 mg per dl. His systemic blood pressure was low , at 105/50 mmHg. 
He was diagnosed with acute pneumonia, acute renal failure and sepsis. a | Chest 
radiograph showing right lower lobe consolidation consistent with pneumonia. At this 
time, the patient was breathing spontaneously with 6 litres nasal oxygen that increased 
his oxygen saturation to 91%. b | Chest radiograph taken 24 hours later showing an 
endotracheal tube in place (arrows) for positive- pressure ventilation with bilateral 
opacities, consistent with the Berlin radiographic criteria. At this time, the patient had a 
partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) ratio of 
125 mmHg on positive- pressure ventilation with a tidal volume of 6 ml per kg predicted 
body weight and a positive end- expiratory airway pressure of 15 cmH2O. The patient also 
had a central line (arrowhead) inserted for administration of fluids and vasopressors as he 
progressed to developing septic shock. Time elapsed between the images demonstrates 
the potential window for early acute respiratory distress syndrome (ARDS) detection and 
early administration of therapies designed to prevent progression.
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lung volume is much smaller than normal, a phenom-
enon termed baby lung, identified and illustrated first 
with CT scans; this concept of the baby lung accounts 
for the low compliance of the respiratory system because 
it identifies the areas of the lung that are consolidated 
with oedema and inflammation and associated atelec-
tasis157. Thus, lower tidal volumes are needed in ARDS 
to prevent regional overdistension, as described above. 
However, scaling tidal volume to PBW targets estimated 
healthy lung size, although aerated baby lung volume 
can differ substantially between patients. Although the 
crucial importance of the use of a low tidal volume is 
now universally accepted, the best method for scaling 
tidal volume to patient- specific surrogates of stress or 
strain is still debated158,159 and warrants further inves-
tigation. Targeting airway driving pressure (plateau 
pressure minus PEEP) is one strategy for tailoring tidal 
volume to patient- specific mechanics that has gar-
nered considerable attention159, but a universally safe 
threshold has yet to be validated in a prospective trial. 
For patients with mild lung injury at lower risk of bio-
physical injury, the benefit conferred by lowering tidal 
volume should be weighed against risks of more aggres-
sive sedation or use of paralytics if needed to achieve 
the intended tidal volumes. Real- time bedside imaging 
techniques such as electrical impedance tomography 
hold some potential to identify overdistension or tidal 
recruitment with each breath, which could be useful for 
monitoring protective ventilation and to individualize 
ventilator strategy.
PEEP. PEEP (5–20 cmH2O) is a key element of protec-
tive ventilation91 and is routinely applied in all patients 
with ARDS to facilitate adequate oxygenation and 
maintain alveolar recruitment. The ideal PEEP might 
be sufficiently high to prevent cyclic opening and col-
lapse of distal airspaces during tidal ventilation yet low 
enough to avoid tidal overdistension. Unfortunately, 
there is still not a reliable method to assess at the bed-
side the risk- to-benefit ratio of different PEEP levels in 
individual patients. Titrating PEEP to offset oesopha-
geal pressure, a surrogate of pleural pressure, showed 
promise in a single- centre study160, but the results from 
a follow- up multicentre trial indicate no benefit for 
clinical outcomes for titrating PEEP by an oesophageal- 
guided strategy, compared with empirical high PEEP in 
patients with moderate or severe ARDS161. No multi-
centre clinical trials to date have definitively shown 
that any one PEEP titration strategy provides superior 
patient- centred outcomes162–164. However, in accordance 
with data from studies assessing lung recruitability with 
CT scan156, a meta- analysis of these trials suggests that 
higher levels of PEEP might be preferable in moderate 
or severe ARDS but not in patients with mild ARDS165. 
Recruitability is a term used to identify distal airspaces 
of the lung that may be collapsed or oedematous that 
could be inflated with higher levels of PEEP, therefore, 
participating in gas exchange. However, a recent study 
reported worse outcomes with a strategy of aggressive 
recruitment manoeuvres (to open the collapsed lung) 
and very high PEEP in patients with moderate or severe 
ARDS receiving 6 ml per kg PBW tidal volume166. 
To maximize benefit and limit the risk of overdistension, 
further reduction in tidal volume may be necessary when 
using high PEEP. The role of recruitment manoeuvres in 
managing ARDS is uncertain at this time167; whereas a 
brief recruitment manoeuvre (for example, 30 seconds 
of continuous airway pressure applied at 30 cmH2O) 
may transiently improve oxygenation in some patients, 
the impact of repeated manoeuvres with higher airway 
pressures and for a longer duration on clinical outcomes 
remains unclear168.
Prone positioning. By modifying the regional distri-
bution of transpulmonary pressure, prone positioning 
decreases regional heterogeneity of lung aeration, lead-
ing to an improvement of gas exchange and a decreased 
risk of mechanical lung injury169. In the multicentre 
PROSEVA trial170, prone positioning improved sur-
vival and shortened the duration of mechanical venti-
lation compared with supine positioning. Unlike prior 
trials that yielded mixed results, PROSEVA enrolled 
only patients with moderate or severe ARDS (PaO2/
FiO2 <150 mmHg) (Box 1), used prone positioning early 
in the patient’s course, prescribed the prone position for 
at least 16 hours per day, tailored treatment course to 
patient recovery and used concomitant low tidal volume 
ventilation — all potential requisites for therapeutic 
efficacy171. Long sessions of the prone position are now 
recommended in most patients with severe ARDS172.
Neuromuscular blockade. In spontaneously breathing 
patients with acute lung injury, it is possible that elevated 
transpulmonary pressures may exacerbate the degree 
of lung injury, thereby raising the question of whether 
intubation and ventilation with lower tidal volumes and 
reduced transpulmonary pressure might be beneficial173. 
In addition, owing to a high respiratory drive, ventilated 
patients with ARDS frequently exhibit strong respiratory 
effort even when receiving high doses of sedatives. This 
respiratory effort may result in severe patient–ventilator 
dyssynchronies and increased mechanical lung injury 
owing to high transpulmonary pressures and/or cyclic 
atelectasis173,174. Paralysis can prevent these effects; thus, 
neuromuscular blockade may decrease mechanical 
lung injury. In a multicentre trial in patients with severe 
ARDS, infusion with the neuromuscular- blocking drug 
cisatracurium for 48 hours improved adjusted survival 
and ventilator- free days compared with deep sedation 
without cisatracurium175. Results are expected soon 
for a follow- up multicentre trial comparing cisatracu-
rium to protocolized sedation managed according to 
usual care176.
Noninvasive respiratory support. For patients with mild 
ARDS (Box 1), avoiding invasive mechanical ventilation 
altogether may be beneficial. Invasive positive- pressure 
ventilation and the related co- interventions carry their 
own risks: sedative infusions that predispose to delirium, 
decreased mobility that predisposes to neuromuscular 
weakness and risk of ventilator- associated pneumonia, 
among other complications177,178. Noninvasive positive- 
pressure ventilation improves oxygenation179 and is used 
often in patients with mild ARDS but without a clear 
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benefit on outcome180; device interface may influence 
patient tolerance and efficacy181,182. High- flow oxygen 
(for example, up to 60 l per min) via large- bore nasal 
cannula is safe, well tolerated and effective in supporting 
patients with mild ARDS, in part by providing low level 
PEEP and modestly increasing carbon dioxide excre-
tion151,183. As mentioned earlier, one recent study found 
that high- flow nasal cannula led to lower mortality than 
noninvasive ventilation or usual care151, and additional 
studies are ongoing. The optimal threshold to proceed to 
intubation and the drawbacks of delaying invasive sup-
port in patients who are progressing towards such have 
not been well defined.
Fluid management
Dating back to 1978, several preclinical studies indi-
cated that elevated lung vascular hydrostatic pressure 
would increase the quantity of pulmonary oedema in 
animal models of ARDS184. In 2006, a randomized clin-
ical trial in 1,000 patients with ARDS demonstrated 
that adopting a fluid- conservative approach after 
vasopressor- dependent shock had resolved led to an 
increase in ventilator- free days and improved oxygen-
ation index185. In the trial, the fluid- conservative arm 
was guided by a detailed algorithm that required meas-
urement of central venous or pulmonary arterial wedge 
pressure measurements every 4 hours to determine the 
use of diuretics to achieve lower vascular filling pres-
sures. Since that trial, a simplified fluid- conservative 
approach has been recommended to reduce overall 
fluid balance by 500–1,000 ml per day in patients with 
ARDS who no longer have shock by reducing intra-
venous fluids and using diuretics. In the presence of 
haemodynamic instability, transpulmonary thermo-
dilution estimation of extravascular lung water could 
help identify risk of exacerbating pulmonary oedema 
with a volume challenge, potentially helping inform 
resuscitation. Some have cautioned against overly con-
servative fluid management, citing a small study that 
suggested that a fluid- conservative strategy might be 
associated with long- term cognitive impairment; how-
ever, methodological issues, potential survivorship bias 
and underpowering limit definitive conclusions185,186. 
This trial also demonstrated no value in using a pulmo-
nary arterial catheter compared with a central venous 
fluid catheter to guide fluid management, as mentioned 
above121. No randomized controlled trial has assessed 
con servative fluid therapy in children with ARDS, but one 
observational study indicated that elevated cumulative 
fluid balance on day 3 of PARDS was associated with 
higher mortality, especially in patients with concomitant 
acute kidney injury187.
Rescue therapies
To maximize efficacy, therapies for ARDS should be 
instituted early in the patient’s course. Some patients 
experience continued clinical deterioration despite 
optimized standard therapies; in this scenario, clinicians 
may consider use of so- called rescue therapies. Although 
no rescue therapy has been definitively proved to be 
beneficial, several interventions described below may 
have value188.
Veno- venous extracorporeal membrane oxygenation. 
Veno- venous extracorporeal membrane oxygenation 
(ECMO) is a treatment in which blood is circulated 
outside of the body for oxygenation on a gas- permeable 
membrane. ECMO has been proposed as a rescue ther-
apy for patients with established very severe ARDS; 
for these trials, patients are typically those with severe 
ARDS (Box 1) in whom sufficient correction of gas 
exchange is inconsistent with lung- protective ventila-
tion189. Observational data from the 2009 influenza A 
H1N1 virus epidemic suggested that ECMO rescue may 
have a role for patients with refractory hypoxaemia due 
to isolated pulmonary failure190. One trial in 249 patients 
with very severe ARDS, refractory hypoxaemia and/or 
hypercapnia randomly assigned participants to ECMO 
or continued conventional treatment. The trial reported 
an 11% absolute reduction in 60-day mortality with 
ECMO with ventilator settings targeting very low tidal 
volumes to achieve a plateau airway pressure less than 
24 cmH2O, compared with the now conventional strat-
egy of 6 ml per kg PBW tidal volumes and plateau air-
way pressures up to 30 cmH2O191. However, this clinically 
substantial effect for survival did not achieve statistical 
significance (P = 0.09), leaving the role of ECMO in 
very severe ARDS open for debate192. The best poten-
tial candidates for ECMO are patients with very severe 
ARDS within the first week of mechanical ventilation 
and without multiple organ failure189,191. To optimize the 
risk- to-benefit ratio, ECMO should be provided only in 
centres experienced in both the care of severe ARDS and 
the use of extracorporeal support189.
Extracorporeal CO2 removal. Extracorporeal CO2 removal 
partially removes CO2 from the venous blood using a 
moderate (0.5-1 l per min) extracorporeal blood flow. 
This method permits the use of very low tidal volume 
(3–4 ml per kg PBW) without causing severe respiratory 
acidosis193. This so- called ultra- protective strategy has 
been shown to attenuate biomarkers of inflammation 
in bronchoalveolar lavage and blood in pilot trials in 
humans194,195, indicating that some patients experience 
ongoing VALI with conventional protective ventilation. 
As with all extracorporeal methods, extracorporeal 
CO2 removal carries its own risks, especially bleeding. 
Pending the results of ongoing studies, the benefit of 
ultra- protective ventilation associated with extracorpor-
eal CO2 removal on outcomes in patients with ARDS 
remains unknown.
Glucocorticoids. Methylprednisolone was among 
the first therapies tested in trials for preventing acute 
lung injury143,144, intuitively appealing for its anti- 
inflammatory properties. Up to one- fifth of patients 
with ARDS receive systemic steroids5, although their 
efficacy for attenuating lung injury remains unclear. 
Although some have reported a positive effect of steroids 
on survival196, a multicentre trial of methylprednisolone 
versus placebo for persistent moderate to severe ARDS 
observed no survival benefit (7–28 days duration)197. 
Steroids accelerated resolution of respiratory failure and 
circulatory shock but also increased risk of neuromus-
cular weakness; patients initiating steroids >14 days after 
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ARDS onset experienced increased mortality. Thus, 
steroids should probably not be initiated 2 weeks after 
ARDS onset and have an uncertain risk- to-benefit ratio 
even when initiated earlier, unless the specific cause 
of ARDS is Pneumocystis carinii pneumonia198. The 
effectiveness of steroids as adjunct therapy in P. carinii 
pneumonia may be related to anti- inflammatory effects, 
although the benefit has not been demonstrated con-
vincingly in other pathogenic causes of ARDS. On bal-
ance, the role for corticosteroids in early ARDS remains 
controversial owing to mixed results from existing lit-
erature and no definitive large- scale trial in the era of 
lung- protective ventilation.
Inhaled pulmonary vasodilators. Inhaled nitric oxide 
and prostaglandin achieve selective vasodilation of the 
pulmonary circulation, improving ventilation- perfusion 
matching and, transiently, oxygenation in patients with 
ARDS199. However, a benefit in patient- centred out-
comes such as mortality has not been demonstrated200. 
Pulmonary vasodilation could benefit patients with 
ARDS in whom associated acute cor pulmonale (right 
heart failure) is contributing to circulatory failure201.
Alternative ventilator modes. High- frequency oscilla-
tory ventilation (HFOV) is a mode of ventilation sup-
port that uses very rapid respiratory rates and very low 
tidal volumes in an attempt to maximize lung recruit-
ment and avoid cyclic alveolar collapse. In two recent 
trials in adults with ARDS202,203, HFOV conferred no 
benefit compared with conventional ventilation, and 
in one trial mortality was increased. Thus, HFOV 
should be used with extreme caution, if at all, in adult 
ARDS. HFOV is more commonly used in children with 
ARDS204, and the PROSPECT study is currently evaluat-
ing its effectiveness using a factorial design. Ventilation 
modes that combine controlled breaths and unassisted 
spontaneous breaths, such as airway pressure release 
ventilation, may improve oxygenation and haemo-
dynamics while decreasing the need for sedation205,206. 
However, concern for VALI risk warrants its limited use 
until studied further207.
Other pharmacological or adjunct therapies. Multiple 
pharmacological therapies to improve clinical outcomes 
in ARDS have been studied in phase II and phase III trials, 
but none have shown efficacy. The list of unsuccessful 
therapies includes surfactant replacement, aerosolized 
and intravenous β2-adrenergic agonists, prostaglandin E1, 
activated protein C, antioxidants, omega-3 supplemen-
tation, ketoconazole (an anti- fungal), lisofylline (an 
anti- inflammatory), recombinant human factor VIIa, 
IFNβ1α, granulocyte–macrophage colony- stimulating 
factor and statins208. However, it is certainly possible that 
one or more of these treatments might have been effec-
tive if a predictive enrichment strategy had been incor-
porated in the trial design, as illustrated in a recent 
study114. In addition, optimal targets for arterial oxy-
genation and arterial CO2 concentration have not been 
defined in ARDS or other critical care conditions; once 
the targets are established, it may be possible to test more 
specific oxygenation targets in clinical trials.
Quality of life
The longitudinal evaluation of survivors of ARDS helped 
spark a research agenda tracking long- term morbidity 
after critical illness; different assessments of QOL and 
function have been used in ARDS survivors. Through 
the mid-1990s, long- term outcomes in ARDS focused 
primarily on the pulmonary system209–211. Over the past 
two decades, the assessment of longer- term outcomes 
has expanded to include several new methods for clin-
ical assessments. These methods have included QOL 
measures focused on limitations in functional domains, 
including muscle weakness and quantitative walking dis-
tance, as well as neurocognitive measures that include 
attention, memory, concentration and mood disorders. 
In addition, data have been collected on caregiver bur-
den, medical complexity and increased health- care costs. 
Here, we consider the evolution of outcome measures in 
survivors of ARDS.
Early reports observed that some survivors of ARDS 
experienced obstructive and restrictive ventilatory defi-
cits that persisted for weeks to months after recovery 
from acute illness209–211. Variability in outcome among 
survivors may be related to differences in study sample 
selection, clinical management during the acute illness, 
duration and completeness of follow- up, heterogeneity 
in baseline pulmonary disease and variable contributions 
from long- term respiratory muscle and diaphragmatic 
muscle weakness. Nevertheless, most patients recover 
near- normal pulmonary function within 6–12 months 
after ARDS209–211.
QOL studies have consistently demonstrated a decre-
ment in physical function domains among survivors of 
ARDS. Early reports postulated these decrements might 
be due to exercise limitation from residual pulmonary 
function abnormalities212–214. Later studies combined 
pulmonary and functional outcome measures with QOL 
assessments, observing that both pulmonary function 
and self- perceived overall health gradually improve 
through 6 months after the acute illness. However, the 
severity of disability was not wholly explained by changes 
in pulmonary function or respiratory symptoms215. The 
aetiology of this reported dysfunction was uncertain. 
A later study combined measures of pulmonary function 
with an evaluation of quality- adjusted life years using the 
Quality of Well- Being Scale (a general health question-
naire that measures well- being over the previous 3 days 
in terms of physical activities, social activities, mobility 
and symptoms) and found that ARDS survivors had 
poor quality- adjusted survival associated with an impor-
tant illness burden. Again, the specific contributors to 
this dysfunction remained unclear216.
A subsequent study combined serial QOL, pulmo-
nary function and 6-minute walk test (a commonly used 
test to assess cardiopulmonary capacity) data with in- 
person history and physical examination and an evalua-
tion of pattern and cost of health- care utilization217. With 
more detailed follow- up evaluations, these investigators 
observed that survivors of ARDS had significant exercise 
limitation and poor physical QOL at 1-year follow- up 
related to marked muscle wasting and weakness; myriad 
physical disabilities including heterotopic ossification, 
joint contractures and tracheal stenosis; and cosmetic 
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concerns related to scarring at tracheostomy, central 
line or chest tube sites. This study focused attention on 
muscle dysfunction as a major morbidity after ARDS 
and served to highlight the prevalence and persistence 
of medical complexity after critical illness217. This same 
group of investigators continued follow- up to 5 years 
after ARDS and noted persistence of disability and com-
promised QOL, which were associated with increased 
cost and health- care use218. These findings are robust and 
have been replicated by many other investigators219–221.
Hopkins and her group were the first to describe neuro-
cognitive and mood disorder outcomes in survivors of 
ARDS. They noted important decrements in attention, 
concentration, processing speed, memory and executive 
function that persisted up to 2 years after discharge from 
intensive care222,223. Post- traumatic stress disorder in 
patients with ARDS has also been described and is asso-
ciated with decrements in the mental health domains of 
the 36-Item Short Form Survey (SF-36) QOL measure213. 
These observations have led the way for other investiga-
tors to evaluate neurocognitive dysfunction and its risk 
factors in ARDS and other survivors of critical illness, 
including hypoglycaemia during the intensive care 
stay224, hypoxaemia and fluid resuscitation186, duration 
of delirium225 and premorbid functional status226.
The observation of persistent muscle wasting and 
weakness in ARDS survivors has spawned intense 
interest in an entity described as intensive care unit- 
acquired weakness (ICUAW), which is the consequence 
of a myosin depletion myopathy and axonopathy occur-
ring in isolation or together227. Injury to the diaphragm 
and muscles of the axial skeleton is due at least in part 
to upregulation of the ubiquitin- proteasome pathway 
and marked proteolysis that begins within hours of the 
critical illness228 and may continue throughout the first 
week of the illness229. Recent seminal observations show 
that muscle repair after an episode of critical illness may 
be differential and the recovery of contractile force and 
muscle mass may be discordant at long- term follow- up230.
One challenge for studies of long- term outcomes is 
knowing the baseline status of the patients with ARDS. 
Thus, the extent to which the deficits manifested before 
developing ARDS is not always clear. In addition, the 
deficits may be a function of prolonged and severe 
critical illness rather than specifically from ARDS.
Outlook
In the past two decades, outcomes from ARDS have 
improved considerably from the first reports of the syn-
drome, in which the majority of patients did not survive. 
However, mortality remains a serious threat, and long- 
term complications remain common and problematic 
in survivors. Additional research on several fronts may 
help to improve prognosis. From a mechanistic perspec-
tive, there is a need for strategies that can mitigate lung 
endothelial and epithelial injury and novel approaches 
that promote lung endothelial and epithelial repair. In 
addition, there is a need to optimize preclinical models for 
testing novel therapies in ARDS to improve the pipeline 
from drug discovery to improved patient outcomes.
In the clinical setting, increased recognition of ARDS 
in all regions of the world is important to better identify 
patients earlier in their clinical course so that supportive 
care with lung- protective ventilation and a conservative 
fluid approach can be implemented. Prognostic and/or 
predictive enrichment approaches that include bio-
logical and clinical variables in randomized trials may 
improve the chances of identifying responsive subsets of 
patients with ARDS. Some have questioned whether the 
syndromic definition of ARDS will continue to be useful 
given its lack of specificity, overlap with other distinct 
syndromes (that is, ARDS mimics) and the relentless 
failure of pharmacotherapeutics in this condition; how-
ever, there is not yet a consensus within the field on a 
suitable alternative approach.
There is new evidence that the degree of pulmonary 
oedema can be quantified on the chest radiograph231, a 
method that can applied rapidly for assessing all four 
quadrants of the standard anterior–posterior radiograph 
in the intensive care unit. In addition, a clinically practical 
method (the ventilatory ratio) for estimating pulmonary 
dead space has been validated232. Thus, a modified lung 
injury score that incorporates oxygenation abnormali-
ties (PaO2/FiO2), the level of PEEP, the pulmonary dead 
space and the degree of pulmonary oedema may prove 
useful to combine with the promising biological variables 
for risk stratification in clinical trials. Novel diagnostic 
approaches may improve our ability to identify and treat 
causative pathogens in patients with ARDS, thereby 
improving patient outcomes233. Extracorporeal therapies 
may provide life- sustaining support for severe ARDS234. 
Multi- pathway targeted cell- based therapies such as 
mesenchymal stromal cells show promise as a potential 
therapeutic option because they have the capacity to 
reduce lung vascular injury, restore alveolar epithelial 
fluid transport properties to remove alveolar oedema-
tous fluid and switch the pro- inflammatory responses to 
a pro- resolving paradigm235,236. Finally, increased under-
standing of the importance of long- term patient- centred 
outcomes may lead to both improved mechanistic under-
standing of the causes of these sequelae and improved 
efforts to design trials that target these symptoms237.
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